Pacira BioSciences, Inc.
$ 25.02
-2.19%
07 Aug - close price
- Market Cap 997,344,000 USD
- Current Price $ 25.02
- High / Low $ 25.68 / 24.93
- Stock P/E 71.49
- Book Value 16.63
- EPS 0.35
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.02 %
- 52 Week High 27.66
- 52 Week Low 18.80
About
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.
Analyst Target Price
$30.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-04-30 | 2026-02-26 | 2025-11-06 | 2025-08-05 | 2025-05-08 | 2025-02-27 | 2024-11-06 | 2024-07-30 | 2024-05-07 | 2024-02-29 | 2023-11-02 |
| Reported EPS | 0.44 | 0.6 | 0.32 | 0.7 | 0.74 | 0.62 | 0.91 | 0.79 | 0.89 | 0.62 | 0.89 | 0.72 |
| Estimated EPS | 0.27 | 0.56 | 0.6 | 0.65 | 0.71 | 0.6 | 0.8303 | 0.7 | 0.7 | 0.62 | 0.87 | 0.78 |
| Surprise | 0.17 | 0.04 | -0.28 | 0.05 | 0.03 | 0.02 | 0.0797 | 0.09 | 0.19 | 0 | 0.02 | -0.06 |
| Surprise Percentage | 62.963% | 7.1429% | -46.6667% | 7.6923% | 4.2254% | 3.3333% | 9.5989% | 12.8571% | 27.1429% | 0% | 2.2989% | -7.6923% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCRX
2026-08-08 07:11:16
Pacira BioSciences announced inducement awards granted to five new employees on August 4, 2026, under its Amended and Restated 2014 Inducement Plan. These awards, approved by the People & Compensation Committee without stockholder approval in accordance with Nasdaq Listing Rule 5635(c)(4), include stock options for 8,500 shares and restricted stock units for 14,200 shares of Pacira common stock. The grants serve as a material inducement for their employment with the company.
2026-08-08 06:09:58
Wall Street Zen has upgraded Pacira BioSciences (NASDAQ:PCRX) to a "strong-buy" rating from "buy," despite the broader analyst consensus remaining "Hold" with an average price target of $29.80. The company reported strong quarterly earnings, beating analyst estimates with EPS of $0.73 and revenue of $192.4 million, a 6.2% increase year-over-year. Institutional investors hold a significant 99.73% of the company's shares.
2026-08-07 20:09:49
Pacira BioSciences announced inducement grants of stock options and restricted stock units (RSUs) to seven new employees. These grants, totaling 19,850 stock options and 11,000 RSUs, were made outside the company's existing equity incentive plans as an inducement material to the new hires' employment in accordance with Nasdaq Listing Rule 5635(c)(4). The grants vest over four years, subject to continued employment.
2026-08-07 19:09:58
State Street Corporation has disclosed a beneficial ownership of 2,059,977 shares, or 5.2%, of Pacira BioSciences Inc. common stock, as detailed in a Schedule 13G SEC filing. This filing indicates that State Street, along with its investment adviser subsidiaries, holds shared voting power over 1,944,697 shares and shared dispositive power over all 2,059,977 shares. The ownership is primarily for investment purposes, with no sole voting or dispositive power reported, meaning control is exercised jointly through entities like SSGA Funds Management, Inc. and various State Street Global Advisors affiliates.
2026-08-06 19:09:58
This article examines the latest analyst forecasts for Pacira BioSciences, Inc. (NASDAQ:PCRX) following its second-quarter results. It provides an overview of the consensus earnings estimates and how they have changed over time, along with an assessment of the company's financial performance and future prospects according to market analysts. Investors can gain insights into the potential trajectory of PCRX based on these expert opinions.
2026-08-06 11:41:15
Pacira BioSciences announced the publication of positive two-year results from its Phase 1 clinical trial for PCRX-201, an investigational gene therapy for knee osteoarthritis, in the Annals of the Rheumatic Diseases. The study found that a single intra-articular injection of PCRX-201 was well-tolerated and showed improvements in pain, stiffness, and function for up to two years. The company is advancing PCRX-201 into its Phase 2 ASCEND trial, with initial topline data expected by year-end 2026.
